Pharsight

Cytalux patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9333270 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US9061057 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US10881747 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US9789208 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US9341629 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US9254341 ON TARGET LABS Methods of manufacture of pteroyl-amino acid-fluorescent dyes
Oct, 2033

(9 years from now)

Cytalux is owned by On Target Labs.

Cytalux contains Pafolacianine Sodium.

Cytalux has a total of 6 drug patents out of which 0 drug patents have expired.

Cytalux was authorised for market use on 29 November, 2021.

Cytalux is available in solution;intravenous dosage forms.

Cytalux can be used as cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.

Drug patent challenges can be filed against Cytalux from 29 November, 2025.

The generics of Cytalux are possible to be released after 04 October, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 29, 2026
New Indication(I-905) Dec 16, 2025
Orphan Drug Exclusivity(ODE-390) Nov 29, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using PAFOLACIANINE SODIUM ingredient

NCE-1 date: 29 November, 2025

Market Authorisation Date: 29 November, 2021

Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CYTALUX family patents

Family Patents